Sakar Healthcare Ltd
Sakar Healthcare Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
Sakar Healthcare Ltd Q3 FY26 key numbers
- Revenue
- Oncology revenues for FY’26 are expected to grow around 30% over FY’25, with Q3 at INR31 crores (INR19 crores export, INR12 crores domestic).
As stated in Sakar Healthcare Ltd's Q3 FY26 earnings call transcript · published 4 Jul 2026. Reported figures, not investment advice.
The short version
Oncology revenues for FY’26 are expected to grow around 30% over FY’25, with Q3 at INR31 crores (INR19 crores export, INR12 crores domestic). Oncology segment expected to grow 60%-70% year-on-year in FY’27, building on ~30% growth in FY’26. - Oncology revenues forecasted to cross INR 200 crores in FY’27 from approx.
From Sakar Healthcare Ltd's Q3 FY26 earnings-call transcript · updated 3 Sept 2026.
Revenue & Sales Performance
- Oncology revenues for FY’26 are expected to grow around 30% over FY’25, with Q3 at INR31 crores (INR19 crores export, INR12 crores domestic).
- For FY’27, anticipated oncology revenue growth is 60% to 70% year-on-year, potentially crossing INR200 crores.
- Significant ramp-up expected due to 100+ marketing authorization submissions pending approval within 12 months and 200 dossiers with partners.
- Tech transfer projects with major pharma companies, including Accord/Intas, expected to start contributing from FY’27 onwards.
- Imatinib technical transfer with Accord will commence end March FY’26; other tech transfer molecules to follow.
2 more points from Sakar Healthcare Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
Read what Sakar Healthcare Ltd said on margins in the Q3 FY26 call
Free account with your mobile number. We text a one-time code, no password.
Capital Expenditure Plans
- For FY’26, Sakar Healthcare incurred a capex of approximately INR 39 crores till nine months, primarily towards plant and machinery setups and utilities as per revised capacity requirements.
- The major planned capex has been completed, and no significant further capex is expected for FY’27.
- Maintenance capex is estimated at around INR 65 lakhs per quarter, related to repairs and upkeep of existing plants.
2 more points from Sakar Healthcare Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Order Book & Pipeline
See what Sakar Healthcare Ltd said on order book & pipeline — free account, 30 seconds.
Sakar Healthcare Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹87 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sakar Healthcare Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules Ltd (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn Ltd (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharmaceuticals Ltd (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Arthneeti Pro · Annual
Sakar Healthcare Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sakar Healthcare Ltd Q3 FY26 results?
Oncology revenues for FY’26 are expected to grow around 30% over FY’25, with Q3 at INR31 crores (INR19 crores export, INR12 crores domestic). Oncology segment expected to grow 60%-70% year-on-year in FY’27, building on ~30% growth in FY’26. - Oncology revenues forecasted to cross INR 200 crores in FY’27 from approx.
What is Sakar Healthcare Ltd share price analysis?
Sakar Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 54.0 with a market cap of ₹1,948 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sakar Healthcare Ltd planning capital expenditure?
For FY’26, Sakar Healthcare incurred a capex of approximately INR 39 crores till nine months, primarily towards plant and machinery setups and utilities as per revised capacity requirements.
Keep Sakar Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.